Blog

Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland

Oct 13 • 3 min read

Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce it has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin, a compound found in psychedelic mushrooms, for the treatment of…

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

Oct 12 • 4 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Day. The session, attended by members of COMPASS Pathways’ executive leadership and…

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Oct 12 • 3 min read

atai Life Sciences N.V. (Nasdaq: ATAI) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD). Initial results indicate that KUR-101 is safe and generally well-tolerated….

What Have We Learned So Far?: Mindshifting Moments #14

Oct 12 • 1 min read

In this special edition of Mindshifting Moments… Host Margaret Williamson reviews all of the show’s most memorable, and enlightening, moments spanning the first several episodes of Mindshifting Moments. We’ll Return With More Special Guests Next Week With so much new information being digested from this show on a weekly basis, we needed to slow down…

Anand Shahi Compares Psychedelics and Cannabis Investing – Podcast Episode #21

Oct 12 • 1 min read

On this episode of the Psychedelic Invest Podcast, we welcome Anand Shahi of BAR Capital. BAR Capital is a family office focused on continuously raising the standards of excellence for the stewardship of wealth. Tune in to learn more about how the cannabis industry relates to psychedelics and how trends and patterns might allow us…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556